Professor Zulf Mughal, M.D., FRCP – Leading Authority on GACI & ENPP1 Deficiency
World-Class Specialist in Rare Genetic Mineralization Disorders
Professor Zulf Mughal is a globally recognized pediatric endocrinologist and bone disorders expert at the Royal Manchester Children’s Hospital in the UK, with over 30 years of experience diagnosing and managing rare metabolic bone diseases including Generalized Arterial Calcification of Infancy (GACI) and ENPP1 deficiency.
Dr. Mughal’s clinical work is dedicated to understanding the complex biology behind conditions that lead to metastatic calcification of soft tissues — particularly ENPP1 deficiency, the genetic cause of GACI and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) — and helping families find answers, care, and support.
What Is GACI & ENPP1 Deficiency?
ENPP1 deficiency is a rare, lifelong metabolic genetic disorder caused by mutations in the ENPP1 gene. These mutations disrupt regulation of pyrophosphate (PPi), a molecule that normally prevents abnormal mineral deposition. Without enough PPi, calcium builds up in soft tissues — especially arteries — leading to Generalized Arterial Calcification of Infancy (GACI).
In many cases:
- Infants develop calcified, narrowed arteries that restrict blood flow and can lead to severe cardiovascular complications.
- Roughly half of infants born with GACI do not survive past six months without critical care.
- Survivors often develop ARHR2, a pediatric bone condition with rickets, growth impairment, and significant skeletal issues.
ENPP1 deficiency can also affect hearing, joints, skin, eyes, and overall quality of life across childhood and into adulthood.
Dr. Mughal’s Mission: Early Diagnosis, Expert Care, and Community Support
In the Behind the Mystery: ENPP1 Deficiency segment, Dr. Mughal explains how crucial rapid, accurate diagnosis is for ENPP1 deficiency and GACI — a condition many clinicians may never see in a lifetime. He highlights:
- How genetic insights uncover the root cause of arterial calcification
- Why early recognition transforms care pathways
- The critical need for specialized support for families facing a rare disease diagnosis
While there is currently no universally approved therapy that directly cures ENPP1 deficiency, Dr. Mughal emphasizes the importance of multidisciplinary clinical management, supportive care, and participation in research and clinical trials that are paving the way toward better outcomes.
Who He Treats
Dr. Mughal works with patients and families across all stages of ENPP1-related disease:
- Newborns with suspected or confirmed GACI
- Children transitioning to pediatric bone disorders (ARHR2)
- Adolescents and adults with late sequelae of ENPP1 deficiency
- Families seeking genetic counseling and long-term management strategies
His work extends from front-line clinical care into global medical advisory roles — collaborating with advocacy organizations like Brighter Hope Foundation and multidisciplinary research networks to accelerate understanding and treatments.
Whether you are newly navigating a rare diagnosis, seeking clarity on treatment options, or searching for community connection, Dr. Mughal and his colleagues emphasize:
Rare-disease education for families and clinicians
Genetic insights that inform accurate diagnosis
Compassionate care tailored to each patient’s journey
Connection to clinical research & support networks
Learn More
Explore resources on ENPP1 deficiency, GACI, and related genetic conditions:
